
Join to view full profile
2485 Hospital DrSuite 200Mountain View, CA 94040
Phone+1 650-988-7480
Fax+1 650-988-7482
Dr. Wieland is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Ophthalmology, 1989 - 1990
Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalResidency, Ophthalmology, 1986 - 1989
University of California (San Francisco)Internship, Internal Medicine, 1985 - 1986
Case Western Reserve University School of MedicineClass of 1985
Certifications & Licensure
NY State Medical License 1989 - Present
CA State Medical License 1990 - 2027
PA State Medical License 1987 - 1989
OH State Medical License 1985 - 1986
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification IntelleChart, MDIntelleSys, A Nextech Company, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification IntelleChart, MDIntelleSys, A Nextech Company, 2014, 2016-2017
- Top MD Consumers Checkbook
Clinical Trials
Publications & Presentations
PubMed
- 40 citationsThe Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery.Shrirang V Ranade, Mark R Wieland, Tammy Tam, Jennifer C Rea, Judit Horvath
Drug Delivery. 2022-12-01 - 13 citationsManagement of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab.Carl C Awh, Giulio Barteselli, Sneha Makadia, Robert T Chang, Jay M Stewart
Ophthalmology. Retina. 2022-11-01 - 14 citationsProphylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial.Clement K Chan, Maziar Lalezary, Prema Abraham, Michael Elman, Wesley Thomas Beaulieu
Ophthalmology. Retina. 2022-06-01
Press Mentions
SUBSPECIALTY NEWS: Prophylactic Eylea, Combination Therapy for Wet AMD, Plasma Kallikrein Inhibitors, Bionic Eye, and MoreAugust 30th, 2019
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









